Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176040 | 0.94 | MEN1 (0.43) | TSHRMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2178944 | 0.87 | MEN1 (0.45) | TSHRMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2175595 | 0.87 | MAPK14 (0.43) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2175010 | 0.87 | MEN1 (0.41) | TSHRMEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2178830 | 0.86 | MAPK14 (0.42) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2177842 | 0.86 | HTT (0.44) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2177234 | 0.86 | MAPK14 (0.44) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2177043 | 0.85 | MAPK14 (0.41) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2175907 | 0.85 | MAPK14 (0.41) | TSHRMAPK14LMNASMN1; SMN2 | |
| SCHEMBL2177627 | 0.85 | MAPK14 (0.41) | TSHRMAPK14LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | TSHR 3182/4885MEN1 3245/4885KMT2A 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.